Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
March 28, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
March 13, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th
March 04, 2019 16:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
January 24, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th
November 08, 2018 07:45 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2018 Financial Results
November 07, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at Two Upcoming Investor Conferences
August 29, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Second Quarter 2018 Financial Results
August 07, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st
June 14, 2018 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces First Quarter 2018 Financial Results
May 09, 2018 08:10 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...